Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802981 · ClinicalTrials.gov registry record
A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)
A clinical trial of Multiple Ground Glass Opacities (GGOs), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 338
- Enrollment target
- 20
- Study locations
NCT03802981: Active study of Multiple Ground Glass Opacities (GGOs), sponsored by Memorial Sloan Kettering Cancer Center.
NCT03802981 is a study of Multiple Ground Glass Opacities (GGOs) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 338 participants. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03802981, a study of Multiple Ground Glass Opacities (GGOs), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.
Conditions Studied
Study Locations (20)
New York
- Roswell Park Cancer Institute (Data Collection Only) - Buffalo
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- New York Presbyterian Hospital - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
California
- University of California San Diego - San Diego
- Stanford University Medical Center (Data collection only) - Stanford
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
Missouri
- George Washington University School of Medicine - St Louis
- Washington University School of Medicine - St Louis
Connecticut
- Hartford Healthcare - Hartford
Illinois
- Rush University Medical Center (Data collection only) - Chicago
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2027-01 |
What the registry record for NCT03802981 still lists
NCT03802981 is an observational study that tracks outcomes without assigning an intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Multiple Ground Glass Opacities (GGOs) appearing as the primary indexed condition, and to 0 interventions.
NCT03802981 names 20 study sites across 10 states, led by New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT03802981 about?
NCT03802981 is a clinical study titled "A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)". The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program...
What is the current status of trial NCT03802981?
This trial is currently active not recruiting. The enrollment target is 338 participants. The study started on 2019-01-09. Estimated completion is 2027-01.
What conditions does trial NCT03802981 study?
This clinical trial studies the following conditions: Multiple Ground Glass Opacities (GGOs).
Who is sponsoring clinical trial NCT03802981?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03802981 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI